- Home
- OXY vs PTGX Comparison
OXY vs PTGX Comparison
Compare OXY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXY | PTGX |
|---|---|---|
| Founded | 1920 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0B | 5.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | OXY | PTGX |
|---|---|---|
| Price | $41.12 | $94.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 9 |
| Target Price | $49.78 | ★ $88.33 |
| AVG Volume (30 Days) | ★ 8.0M | 902.1K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.39 | 0.72 |
| Revenue | ★ $26,601,000,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $296.47 |
| P/E Ratio | ★ $29.54 | $132.27 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.79 | $33.70 |
| 52 Week High | $53.20 | $95.26 |
Technical Indicators
Market Signals| Indicator | OXY | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 70.99 |
| Support Level | $40.90 | $88.30 |
| Resistance Level | $41.78 | $92.80 |
| Average True Range (ATR) | 0.75 | 2.82 |
| MACD | -0.05 | 0.19 |
| Stochastic Oscillator | 17.80 | 94.19 |
Price Performance
Historical ComparisonAbout OXY Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,327 thousand barrels of oil equivalent per day in 2024 at a ratio of roughly 52% oil and natural gas liquids and 48% natural gas.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.